Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil (Ylervoy) in chronic lung allograft dysfunction after bilateral lung transplantation
CTR20242991Phase 3Active
- Sponsor
- Kadmon
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ipilimumab in chronic lung allograft dysfunction (CLAD), sponsored by Kadmon. Started Apr 2025; status: active.
02
Drugs
ipilimumab
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on CTR20242991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242991.